On Friday, Shares of PG&E Corporation (NYSE:PCG), gained 1.40% to $52.89.
PG&E Corporation, declared the appointments of Bernard Cowens as vice president and Chief Information Security Officer and Kathleen Kay as vice president, Business Technology.
“Our ability to effectively manage and protect information is vitally important and challenging. We are very happy to welcome Bernie and Kathy, who both have exceptionally strong backgrounds, to the PG&E team,” said PG&E Corporation Chairman and CEO Tony Earley.
Cowens joins PG&E, effective Aug. 24, from his role as Chief Information Security Officer at First American Financial Corporation. Cowens has extensive experience in information technology and cyber and physical security and formerly held senior and executive-level roles in the private sector and the military.
PG&E Corporation, through its partner, Pacific Gas and Electric Company, transmits, delivers, and sells electricity and natural gas to residential, commercial, industrial, and agricultural customers primarily in northern and central California.
Shares of Ares Capital Corporation (NASDAQ:ARCC), declined -2.00% to $15.72, during its last trading session.
Ares Capital Corporation provided additional details on its financing commitments closed during the second quarter of 2015. Financing commitments made by Ares Capital in the second quarter totaled over $820 million.
“We continued to experience competitive advantages from our size and scale in the second quarter in a year when middle market loans have been light, making almost 60% of our investment commitments to existing portfolio companies,” said Kipp deVeer, Chief Executive Officer of Ares Capital. “We continue to focus on senior secured investments with 65% of our new commitments in first or second lien senior secured loans.”
Below is a description of nine transactions that closed during the second quarter.
Implus Footcare, LLC / Berkshire Partners
Ares Capital served as administrative agent, lead arranger and bookrunner for a $394.0 million senior secured credit facility to support the acquisition of Implus Footcare, LLC by Berkshire Partners. Headquartered in North Carolina, Implus has evolved to become an innovative provider of footwear, outdoor and fitness accessories to its retail partners. Implus’ family of brands comprises Sof Sole, Yaktrax, apara, Airplus, Sneaker Balls, Sof Comfort, Balega, Little Hotties, Perfect, TriggerPoint and ICETrekkers. From insoles, socks and shoe care to seasonal accessories and fitness solutions, Implus proudly distributes its brands to thousands of retail locations across the United States and worldwide.
EN Engineering / General Atlantic
Ares Capital served as administrative agent, joint lead bookrunner and joint lead arranger for a $210.0 million senior secured credit facility to support the acquisition of EN Engineering by General Atlantic. EN Engineering provides comprehensive and dependable engineering, consulting and automation services to pipeline companies, utilities and industrial customers.
Ares Capital Corporation is a specialty finance company that is engaged in closed-end, non-diversified administration investment businesses. The Company’s investment objective is to generate both current income and capital appreciation through debt and equity investments, investing invest primarily in United States middle-market companies.
At the end of Friday’s trade, Shares of MDC Partners Inc (NASDAQ:MDCA), gained 18.43% to $19.34.
MDC Partners declared that its Board of Directors has declared a cash dividend of $0.21 per share on all of its outstanding Class A shares and Class B shares. The quarterly dividend will be payable on or about September 1, 2015 to shareholders of record at the close of business on August 18, 2015.
MDC Partners Inc. provides marketing, activation and communications, and consulting solutions and services worldwide. It operates through two segments, Planned Marketing Services and Performance Marketing Services.
Finally, Oncothyreon Inc (USA) (NASDAQ:ONTY), ended its last trade with -7.56% loss, and closed at $3.30.
Oncothyreon, stated financial results for the second quarter ended June 30, 2015.
Net loss for the three months ended June 30, 2015 was $10.9 million, or $0.11 per basic and diluted share, contrast with a net loss of $6.0 million, or $0.09 per basic and diluted share, for the comparable period in 2014. The $4.9 million enhance in net loss was primarily attributable to the difference in the change in the fair value of warrant liability of $4.3 million. The enhance in net loss was also due to enhances in research and development expenses of $0.3 million and enhances in general and administrative expenses of $0.2 million.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
